ArticleCureus2025
Intraoperative Anaphylaxis to Isosulfan Blue: Recognizing a Rare but Life-Threatening Reaction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isosulfan blue injection (Lymphazurin) is a blue dye injection that is commonly used to map lymphatics in lymphangiography and sentinel lymph node biopsies. A 75-year-old male with a history of hyperlipidemia presented after excision of multiple lesions with plastic surgery, revealing melanoma in situ on the patient's scalp and superficial spreading melanoma with 4 mm margins on the right posterior axilla. During what was expected to be a routine procedure, anesthesia informed the operating room that the patient had become abruptly hypotensive, but responded to a one-time dose of peripheral vasopressors. The patient's chest and face were noticed to be erythematous and edematous when the patient was turned to begin the wide local excision. Welts and hives were noticed to be originating from the area where isosulfan blue was injected. The patient did fully recover from the incident with no unfortunate sequelae, but given this likely anaphylactic event, the patient should never again be exposed to isosulfan blue without direct physician care. Most reactions to isosulfan blue occur on first exposure and, despite its misnomer, have little to no relation to sulfa allergies. This case report and literature review critique the uses and indications for isosulfan blue, as well as discuss the hazards and prevention of these potentially critical reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.